{"id":475536,"date":"2021-04-13T09:03:09","date_gmt":"2021-04-13T13:03:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/"},"modified":"2021-04-13T09:03:09","modified_gmt":"2021-04-13T13:03:09","slug":"sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/","title":{"rendered":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, April  13, 2021  (GLOBE NEWSWIRE) &#8212; <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xH3qeE2rxybXMxV7aR097nDti7ZR3hr0yb9cEcyKs-t4ta37Cnx0Z0dVe-ronzdTtsDqGOaksXHkRnEe7jkCG70hlGdF4WqA26tBLXhLFN8=\" rel=\"nofollow noopener\" target=\"_blank\">SEngine Precision Medicine<\/a><\/strong>, a precision oncology company that pre-tests drugs on patient-derived\u00a0live tumor specimens employing its CLIA certified PARIS<sup>\u00ae<\/sup> Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS<sup>\u00ae<\/sup> Test (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RT4LuJytIzsJCxUDsziainVDkqSw64tizaC58YTnQj1QfS0lB-u0i7epeEEjxLGC6q0VEQ0S0QaSS1kbK0ogCiPBjYkwWg3B8SWWfN7T63Fu2BbdTAoCLp2RxlZr03QJNsF21pUuwWvDc37zrrKaZw==\" rel=\"nofollow noopener\" target=\"_blank\">abstract number 534<\/a>) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021.<\/p>\n<p>The poster presentation highlighted the utility of the PARIS<sup>\u00ae<\/sup> Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that:<\/p>\n<ul type=\"disc\">\n<li>Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples.<\/li>\n<li>For 82% of patient samples tested, the PARIS<sup>\u00ae<\/sup> Test identified at least one drug with good to exceptional response that is either FDA approved or in clinical trials.<\/li>\n<li>In 22\/24 patient tests (91%), the results demonstrated resistance to at least one drug on which the patient\u2019s disease progressed in clinic.<\/li>\n<li>The PARIS<sup>\u00ae<\/sup> Test showed good clinical response concordant with assay results for 10\/12 patients (83%) evaluated for clinical prediction.<\/li>\n<\/ul>\n<p>This study also presents an example of clinical benefit for a patient with ovarian cancer who received an individualized therapy based on PARIS<sup>\u00ae<\/sup> Test results. The patient was diagnosed with stage IV low-grade epithelial serous carcinoma that progressed on multiple rounds of chemotherapies. The patient\u2019s tumor responded to the PARIS<sup>\u00ae<\/sup>-guided treatment Ibrutinib, a targeted drug, that to the study authors\u2019 knowledge has never before been employed for ovarian cancer. Ibrutinib is an FDA approved drug only used to treat mantle cell lymphoma and chronic lymphocytic leukemia.<\/p>\n<p>\u201cThe PARIS<sup>\u00ae<\/sup> Test identified a novel therapy, Ibrutinib, that has successfully controlled the patient\u2019s disease with CA 125 levels dropping by over half during the course of treatment\u00a0and improvement in her symptoms,\u201d noted Heidi Gray, MD, treating physician in the patient case study presented at AACR 2021. \u201cThis is a breakthrough example of the power of phenotypic testing to identify effective treatments for individual patients by scanning a broad menu of oncology drugs.\u201d<\/p>\n<p>\u201cThe PARIS<sup>\u00ae<\/sup> Test adds a new dimension to precision oncology by confronting patients\u2019 tumor cells with drugs outside the body. By harnessing a unique series of algorithms applied to the results of the PARIS<sup>\u00ae<\/sup> Test, drug sensitivity versus resistance is accurately predicted and drug responses are ranked for each patient,\u201d said Carla Grandori, MD, PhD, co-founder and Chief Executive Officer of SEngine Precision Medicine. \u201cThrough this case and others, we have learned that cancer is not so strong after all, even when refractory to multiple chemotherapy regimens. Cancers have vulnerabilities that can be exploited by a growing array of targeted drugs. In the case study presented at AACR 2021, the patient\u2019s tumor responded to Ibrutinib, a well-tolerated drug that could potentially help 10% of patients with ovarian cancer.\u201d<\/p>\n<p>\u201cEvery patient\u2019s cancer is unique, and we observe distinctive patterns of genomic features and targeted drug responses across patients that highlight the need to individualize therapy. Our data provides compelling evidence that the organ of tumor origin only partially matters for determining effective therapies and that supports the use of a range of existing targeted therapies for ovarian cancer,\u201d commented Goldie Lui, PhD, Lead Scientist at SEngine Precision Medicine and first author of this study.<\/p>\n<p>Details related to the poster presentation are as follows:<br \/>Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities<br \/>Lead Author:\u00a0Goldie Lui, PhD<br \/>Senior Author: Carla Grandori, MD, PhD<br \/>Abstract Number: 534<br \/>Session Title: Laboratory Correlates for Targeted Agents<\/p>\n<p>\n        <strong>About PARIS<sup>\u00ae<\/sup> Test<\/strong>\u00a0<br \/>The PARIS<sup>\u00ae<\/sup>\u00a0Test is based on the capability to propagate patient-specific cancer\u00a0cells outside the body\u00a0and is applicable to all solid tumors\u00a0including colon, breast, lung, ovarian and pancreatic cancer. Cancer-derived cells grown\u00a0in 3D outside the body maintain the functionality of the original tumor as well as its genomic characteristics.\u00a0For cancers\u00a0where\u00a0a treatment\u00a0path is not clear, such as\u00a0many metastatic and recurrent cancers,\u00a0the PARIS<sup>\u00ae<\/sup> Test provides crucial information to\u00a0treating physicians\u00a0to\u00a0match the right drug to the right patient.<\/p>\n<p>\n        <strong>About SEngine Precision Medicine<\/strong><br \/>\n        <br \/>SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures grown ex-vivo utilizing patient specific tumor cells.\u00a0As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&amp;D in diagnostics and drug discovery. The Company is commercializing the PARIS<sup>\u00ae<\/sup> Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with phenotypic testing of patient-derived live cells combined with robotics and AI-driven computational tools. SEngine\u2019s CLIA certified PARIS<sup>\u00ae<\/sup> Test generates actionable drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical \/ pharma companies leveraging its precision oncology platform.<\/p>\n<p>Discover more at\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4eY_en_GD2IADZ3pxDt-5H4rO8sBaiblM6LfupXoBJbzOLKDUrJF2kkpgtTwovJDp65cTlGJwCUKnQbw92976bDVOeeFdI4OTFPjC5enXcQ=\" rel=\"nofollow noopener\" target=\"_blank\">SengineMedicine.com<\/a><\/strong>\u00a0and follow the latest news from SEngine on Twitter at\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Rk8fW2NcI_hltsNlNwLmNOLpcHIni6oqxgYtt5fYw8a0CuuYuaKdks4TRJG27W-55kqAAmd--lwuFPP9DUscuPh5C_VX1AsaXTgKxm5V4NM=\" rel=\"nofollow noopener\" target=\"_blank\">@SEngineMedicine<\/a><\/strong>\u00a0and on\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xOsqukMa2Su29sp1xOnmZcyaUZdgK7tGKBjCai_O2y5-D_RHgKArNtVT-I1SbWOOzO42GwnZMgZ2Nwheainfx39Sia7qNUhTa5qtGwcvK8JHNHWryDz8_6oGDk3PTcun\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a><\/strong>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Stephanie Carrington<br \/><strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hw6aLiUDHJCUrn4jtW1oKut6q6dKpX3Bf1RbnsSI5W3tSr-o07c_FHyW3J9DmpLMC-w0ytga04FhpW5xycmuqfUNMlAKJet81IA-nFtbkZzi1TubH7usEnjQtGq1cTr0UA70PgnEsyDcXeA36Asvzw==\" rel=\"nofollow noopener\" target=\"_blank\">stephanie.carrington@westwicke.com<\/a><\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JJj_OBi4vd6t-JpLriIwZIuiqn7oouChNN7KgOfSYCqpfQoo8PGkSqhRdUSE6yN3C72vRKDstHzm9iVEzQj4McvktudCzJD4uMGLhqk9aYh6jaVFGmmuAV4w6reWRhzJvpd3L79n5uE97wCHV7oeSr7I2h9XOu1yWf9-S6xtKXlET9Y1H1c_EWr38fHTUhcgC9227US3EIQee5NpFxF5tL02pZXVyYTpfKiktuCJABLxNcX4XB2kIfF-7TSOjq9DbktCmvLKPKk-0EJmGEn_RzuPdot2e-rGdsk4SQ9-mVFGT07euZRd1e3hbF1SOYEgoi79Vowm3vKzTnOCkCxAIYh19OMapn-fEvcSgNndharl2ZMlAkhZ_QtKip43zJsu\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a>646-277-1282<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/564fdcff-95ff-4021-9bb0-1633fedb10cc\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived\u00a0live tumor specimens employing its CLIA certified PARIS\u00ae Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS\u00ae Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021. The poster presentation highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples. For 82% of patient samples &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-475536","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived\u00a0live tumor specimens employing its CLIA certified PARIS\u00ae Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS\u00ae Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021. The poster presentation highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples. For 82% of patient samples &hellip; Continue reading &quot;SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-13T13:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer\",\"datePublished\":\"2021-04-13T13:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/\"},\"wordCount\":849,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/\",\"name\":\"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\",\"datePublished\":\"2021-04-13T13:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk","og_description":"SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived\u00a0live tumor specimens employing its CLIA certified PARIS\u00ae Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS\u00ae Test (abstract number 534) at the American Association for Cancer Research annual meeting, taking place virtually from April 10-15, 2021. The poster presentation highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in ovarian cancer. In an ovarian cancer cohort of 44 evaluable patient samples, authors found that: Ovarian cancer patient-derived 3D cultures preserve the histopathological and molecular features of original tumor samples. For 82% of patient samples &hellip; Continue reading \"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-13T13:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer","datePublished":"2021-04-13T13:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/"},"wordCount":849,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/","name":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=","datePublished":"2021-04-13T13:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNjA5OCM0MTE4NTgxIzIxOTc1MjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-at-2021-aacr-annual-meeting-demonstrating-clinical-utility-and-predictive-value-of-paris-test-in-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS\u00ae Test in Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475536","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=475536"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/475536\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=475536"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=475536"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=475536"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}